Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain

BACKGROUND: Currently, several biologic agents are available for the treatment of moderate-to-severe plaque psoriasis, including newer agents with similar mechanisms of action and efficacy; therefore, there is a need to evaluate their efficiency in terms of cost effectiveness. OBJECTIVE: This study...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clinicoecon Outcomes Res
Hlavní autoři: Johansson, Erin, Nuñez, Mercedes, Svedbom, Axel, Dilla, Tatiana, Hartz, Susanne
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2018
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6237133/
https://ncbi.nlm.nih.gov/pubmed/30519064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S167727
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky